evipedia.ai
← Back

Acetyl Tetrapeptide-2 for Skin Rejuvenation

Evidence Review created on 09/21/2026 using AI4L / Opus 5

Also known as: Ac-Lys-Asp-Val-Tyr, KDVY, Thymulen-4, Uplevity

Motivation

Acetyl tetrapeptide-2 (also sold as Thymulen-4 and Uplevity) is a short synthetic protein fragment used in skin creams, serums and scalp lotions. Its four building blocks copy a piece of thymopoietin, a messenger made by the thymus, a small gland in the upper chest that shrinks steadily from puberty onward. The idea behind the ingredient is simple: put back on the skin a signal the body makes less of with age.

Ingredient makers have promoted the peptide for firmer, more elastic skin and for faster renewal of the outer skin layer. Interest among people who track biological aging comes from the thymus link, since the shrinking of that gland is one of the clearer markers of an aging immune system. Whether a molecule sitting on the skin surface can reach that machinery at all is contested, and the amount of published human testing is small.

This review examines what is known about acetyl tetrapeptide-2 for skin rejuvenation: where the evidence comes from, who produced it, how far it reaches, and what has never been measured.

Benefits - Risks - Protocol - Conclusion

High-level material that discusses acetyl tetrapeptide-2 by name, or the class of cosmetic peptides it belongs to, in substantial depth.

Content from Rhonda Patrick, Peter Attia, Andrew Huberman, Chris Kresser and Lifespan.io could not be found: each platform covers injectable and oral peptides only, never this molecule or topical cosmetic peptides.

Grokipedia

  • Acetyl tetrapeptide-2

    A dedicated encyclopedia entry covering chemical properties, biological activity, cosmetic applications, research and evidence, and safety and regulation, with the supplier-derived claims kept separate from the independent literature.

Examine

No Examine article exists for acetyl tetrapeptide-2. The site covers ingestible supplements and does not maintain pages on topical cosmetic ingredients.

ConsumerLab

No ConsumerLab article exists for acetyl tetrapeptide-2. ConsumerLab tests ingestible supplements and does not review cosmetic topicals.

Systematic Reviews

Systematic reviews and meta-analyses covering the cosmetic peptide class this ingredient belongs to, and the principal risk of any leave-on topical, built on randomized controlled trials (studies assigning participants to treatment or comparison by chance).

Mechanism of Action

Acetyl tetrapeptide-2 is the acetylated sequence lysine-aspartic acid-valine-tyrosine, reproducing residues 33 to 36 of thymopoietin, a hormone of the thymus gland. Because the thymus shrinks from puberty onward, the ingredient is positioned as surface replacement for a signal that declines with age. In cultured skin cells, the proposed actions are proliferation and maturation of keratinocytes (the cells making up most of the outer skin layer), release of granulocyte-macrophage colony-stimulating factor (a messenger that recruits immune cells), and increased output of fibulin-5 and lysyl oxidase-like 1, two proteins that organize and cross-link elastic fibres. The supplier adds upregulation of focal adhesion proteins, which anchor cells to the surrounding matrix.

A competing explanation applies to the whole class. The molecule weighs 566 daltons and is strongly water-loving, placing it above the roughly 500-dalton ceiling for passive entry through the stratum corneum, the skin’s outer barrier layer. On that reading, measured changes owe more to the vehicle’s hydration and occlusion than to the peptide. The counter-argument is that N-terminal acetylation blocks the enzymes that clip peptides apart, extending survival on the skin, and that hair follicles offer a bypass route.

Pharmacologically, no human data exist on half-life, distribution or metabolism. The peptide has no defined receptor, is broken down by skin surface and epidermal peptidases into its amino acids, and is not expected to reach liver enzymes such as CYP3A4 (a major drug-metabolizing enzyme) in meaningful amounts.

Historical Context & Evolution

The parent molecule was characterized in the 1970s, when thymopoietin was isolated as a thymic hormone that drives maturation of immune cells. Its active core was reduced to the five-residue fragment thymopentin, which was developed as an injectable immune-modulating medicine for immunodeficiency and marketed in parts of Europe. The original intended use, then, was systemic immune restoration, not cosmetics.

The cosmetic adaptation trimmed one residue and capped the sequence, and arrived under the Thymulen-4 trade name as a “thymic factor replacement” for aging skin, supported by cell-culture work reporting faster keratinocyte turnover, more keratin and a large rise in granulocyte-macrophage colony-stimulating factor release within five days. Those findings were never published in a peer-reviewed journal; they circulate through supplier documentation and the consumer press. They have not been refuted either — the point is that nobody outside the supply chain has repeated them.

Around 2015 the ingredient was repositioned by Lipotec, the raw-material manufacturer, under the Uplevity name, with the rationale shifted from immune signalling to elastic-fibre assembly and dermal cohesion, and with in-house testing in women on facial firmness. The shift matters: the marketing claim moved without new independent evidence arriving, and both framings remain live in product literature today.

Expected Benefits

High 🟩 🟩 🟩

No benefit reaches High: there is no replicated randomized trial measuring a human skin endpoint — instrument-measured elasticity, graded wrinkle severity or a validated photodamage scale — with acetyl tetrapeptide-2 as the only variable.

Medium 🟩 🟩

No benefit reaches Medium either: the single randomized trial involving this peptide tested a multi-ingredient scalp lotion, so its clinical endpoints cannot be attributed to the peptide, and the manufacturer’s facial study is unpublished in-house testing.

Low 🟩

Improved Facial Firmness and Elasticity

The manufacturer’s in-house testing of a cream containing 2% of the peptide solution reported firmer, more elastic facial skin after eight weeks. A systematic review of this ingredient class found most such studies lack placebo control or blinding, and this one has never been published in full.

Magnitude: In women aged 40–60 applying the cream twice daily for 56 days, maximal skin deformation fell 25.2%, overall elasticity rose 16%, and the face contour lifted 0.13 cm, as reported in the trade press; the underlying study report is not public.

Reduced Hair Shedding in Acute Telogen Effluvium ⭕️ Not Central to Skin Rejuvenation

A randomized trial in 100 women tested a scalp lotion combining creatine, this peptide and B vitamins against a mild shampoo alone; shedding fell faster and earlier in the treated group. The peptide’s own contribution cannot be isolated. This bears on scalp and hair, not on facial skin quality.

Magnitude: Resting-phase hair density fell at every timepoint with the lotion versus only at week 16 in controls, the between-group difference reaching significance at week 8 (P = 0.0465; P estimates how often a difference this large would appear by chance), with fewer total hairs shed at week 8 (P = 0.0392).

Speculative 🟨

Increased Keratinocyte Stiffness and Cytoskeletal Remodelling

Atomic force microscopy found the peptide stiffened cultured human skin cells across a concentration range. Cell stiffness is a laboratory surrogate for tissue firmness; the basis here is mechanistic only, with no human outcome.

Elastic-Fibre Assembly via Fibulin-5 and Lysyl Oxidase-Like 1

The supplier reports cultured cells raised fibulin-5 and lysyl oxidase-like 1 output up to 2.3-fold and 1.7-fold versus placebo. These are unpublished cell-culture markers from the seller, not skin outcomes.

Epidermal Renewal and Local Immune Signalling

Early cell-culture work behind the Thymulen-4 name reported higher keratinocyte density, more keratin, and a large rise in granulocyte-macrophage colony-stimulating factor within five days. No peer-reviewed report or human confirmation exists.

Benefit-Modifying Factors

  • Barrier gene variants: Loss-of-function variants in the filaggrin gene (filaggrin is the protein that seals the outer skin layer) leave a leakier barrier — plausibly more peptide entry, but also more irritation from the vehicle. No study has tested this interaction.

  • Baseline elasticity and photodamage: The manufacturer’s study recruited women already showing laxity and elasticity loss. Skin still near its baseline has less room to move on instrument measures, so an effect, if real, should be smaller.

  • Sex-based differences: Women lose dermal collagen sharply in the years around menopause, as reviewed for oestrogen and skin. Published human exposure to this peptide is female-only, so any response in men is untested.

  • Pre-existing conditions: Rosacea, atopic dermatitis and seborrhoeic dermatitis (a scaly, flaking rash on oily areas) change both tolerance and barrier permeability, shifting the balance between any benefit and the irritation risk of a leave-on formula.

  • Age within the target range: Epidermal turnover slows with age, which is the stated rationale for the ingredient. Adults past 60 have the largest theoretical gap to close and the least supporting data, since testing stopped at 60.

Potential Risks & Side Effects

High 🟥 🟥 🟥

No risk reaches High: no adverse event has been documented for this peptide in more than one trial — the entire published human exposure is one randomized cosmetic trial, which recorded excellent tolerance.

Medium 🟥 🟥

No risk reaches Medium either: no single trial or consistent observational dataset records a clinical adverse event attributable to acetyl tetrapeptide-2 rather than to a formulation’s vehicle, preservative or fragrance.

Low 🟥

Allergic Contact Dermatitis to the Finished Product

Any leave-on cosmetic can sensitize, and the usual culprits are preservatives, fragrance and plant extracts rather than the peptide. Pooled patch-test data show contact allergy is common in the general population, and no published case names this peptide as the allergen.

Magnitude: Contact allergy to at least one common allergen affects 20.1% of the general population (95% confidence interval 16.8–23.7%, the range in which the true value most likely lies), and 27.9% of women; nickel and fragrance mix lead the list.

Irritation and Sensitization on a Compromised Barrier

Applying non-sterile cosmetic formulas to skin whose barrier is breached — after peels, lasers or microneedling, or over active eczema — raises the chance of stinging, redness and new sensitization to whatever the formula contains. Reviews of emerging cosmetic allergens describe this route; none involves this peptide.

Magnitude: The risk rises with the degree of barrier disruption and is highest in the days before re-epithelialization (the regrowth of the outer skin layer across a wound) after a procedure, and on skin with active dermatitis; the literature reports no outcome figure for this peptide or its finished products.

Displacement of Better-Documented Actives

Committing a routine slot, and budget, to an ingredient whose clinical file is one unpublished manufacturer study means forgoing the measured gains of retinoids, the best-documented topical option. The trade-off is real even where its size is unknown.

Magnitude: Of 15 clinical studies of matrix-stimulating cosmetic peptides, only six used a placebo control and five were double-blind, while tretinoin’s effect on photoaged skin is established in controlled trials; the literature reports no outcome figure for the displacement itself.

Speculative 🟨

Unintended Immune Modulation

The parent pentapeptide shifts immune-cell ratios when injected. Whether a surface-applied fragment reaches skin immune cells at all is unknown; the basis is mechanistic, with no reported clinical event of this kind.

Systemic Absorption

At 566 daltons and strongly water-loving, the molecule should barely cross the outer skin layer, so systemic exposure is expected to be negligible. No human absorption study exists to confirm this, making the reassurance theoretical.

Risk-Modifying Factors

  • Barrier gene variants: Filaggrin loss-of-function carriers, common in people with atopic dermatitis, absorb more of everything applied and sensitize more readily to leave-on formulas.

  • Baseline barrier measurements: Elevated water loss through the skin before starting marks a disrupted barrier, the state in which irritant and allergic reactions to any new leave-on product are most likely.

  • Sex-based differences: Contact allergy is roughly twice as prevalent in women as in men, largely through greater lifetime cosmetic and jewellery exposure rather than any sex-specific response to this peptide.

  • Pre-existing conditions: Active eczema, rosacea and perioral dermatitis (a rash ringing the mouth) lower the irritation threshold; a known positive patch test to any component of the finished formula rules that product out entirely.

  • Age within the target range: Older skin has a thinner, drier stratum corneum and slower repair, so irritant reactions settle more slowly, while immune sensitization becomes somewhat less likely with age.

Key Interactions & Contraindications

  • Prescription topical retinoids (tretinoin, adapalene, tazarotene): Caution. Additive irritation and barrier disruption; consequence is stinging, peeling and higher sensitization risk. Mitigation: alternating evenings, or the peptide in the morning and the retinoid at night.

  • Topical corticosteroids (hydrocortisone, mometasone, clobetasol): Monitor. Prolonged use thins the dermis and works against any firming endpoint, confounding assessment. Mitigation: results are not assessed while a potent steroid is in use on the same area.

  • Over-the-counter benzoyl peroxide: Caution. A strong oxidizer that can degrade peptides on contact, so the consequence is lost activity rather than harm. Mitigation: applications separated by at least 12 hours.

  • Over-the-counter exfoliating acids (glycolic, lactic, salicylic): Caution. These sit at pH 3–4, outside the pH 5–8 range in which the peptide solution is stable; consequence is degradation plus additive irritation. Mitigation: separate days for each.

  • Supplement interactions — oral collagen peptides, hyaluronic acid, vitamin C: No caution required; additive on the same endpoints (hydration, elasticity, wrinkle scores) with no known adverse interaction. Consequence: benefit attribution becomes impossible. Mitigation: staggered introduction, one at a time.

  • Other interventions — microneedling, ablative lasers, medium-depth peels: Caution. These bypass the barrier and can drive non-sterile cosmetic ingredients into the dermis, with granulomatous reactions (persistent inflammatory lumps) reported for cosmetics generally. Mitigation: use resumes only after re-epithelialization.

Populations who should avoid Acetyl Tetrapeptide-2:

  • Anyone with a positive patch test to the peptide or to any component of the finished formula (absolute contraindication)
  • Skin within 72 hours of an ablative laser, medium-depth peel or microneedling, or any wound before re-epithelialization
  • Active, weeping or fissured dermatitis at the application site, until the barrier has healed
  • Direct periocular use of any product not ophthalmologist-tested for the eye area
  • Pregnancy and lactation for products intended for large body-surface application, where no exposure data exist

Risk Mitigation Strategies

  • Open patch test before facial use: The product goes on the inner forearm once daily for 5 consecutive days, with inspection at 48 and 96 hours; this catches the allergic contact dermatitis that leave-on formulas cause.

  • One new product at a time: A single leave-on formula is introduced with the rest of the routine held fixed for 4 weeks, so any reaction, and any benefit, traces to one source.

  • Minimal formula: Fragrance-free products with short ingredient lists carry the lowest sensitization risk, since fragrance mix and preservatives — not the peptide — dominate published cosmetic sensitization.

  • Stability window: Products formulated at pH 5–8 and stored below 25 °C in airless or opaque packaging retain their active; outside that window the peptide degrades and the expected benefit disappears.

  • Post-procedure pause: A gap of at least 72 hours after microneedling, peels or ablative lasers, and until skin is closed, avoids delivery of non-sterile cosmetic material into the dermis.

  • Stop rule: Stinging lasting beyond 10 minutes after application, or redness persisting past 24 hours, marks an irritant reaction and is the point at which use stops, before sensitization develops.

  • The proven base: Daily broad-spectrum sun protection factor 30 or higher stays in place regardless, since ultraviolet exposure drives the collagen and elastin breakdown this ingredient claims to counter.

Therapeutic Protocol

  • Standard regimen: A cream or serum containing 2% of the Uplevity peptide solution, applied twice daily to clean facial skin for at least 56 days — the regimen and duration of the manufacturer’s testing, as reported in the trade press.

  • Competing approach — the Thymulen-4 route: The older epidermal-renewal framing is formulated at 1–3% of the supplier solution, targeting turnover and skin immune defence rather than elastic-fibre assembly; neither approach has been tested against the other.

  • Who popularized each: Lipotec, now part of Lubrizol, developed and promoted the firmness positioning; the dermatologist Gary Goldfaden and Life Extension brought the thymic-renewal framing to the longevity consumer market.

  • Formulation requirements: Added to the water phase of cold formulations, or below 40 °C once an emulsion has formed, at pH 5.0–8.0; the supplier solution is preservative-free and needs the finished product to be preserved.

  • Best time of day: Both applications matter more than either slot. Morning use pairs with sun protection; evening use avoids low-pH acids and benzoyl peroxide, which are usually night-time steps.

  • Half-life: No human half-life exists for topical use. The parent pentapeptide is cleared from plasma so fast that fatty-acid conjugation was developed to extend it; acetylation here blocks the enzymes that clip peptides.

  • Single versus split dosing: Split twice-daily application is standard, because surface residence is short and nothing is stored in tissue; no study has compared once- with twice-daily use.

  • Genetic considerations: No pharmacogenetic variant is known to alter response. Filaggrin loss-of-function variants and collagen-degrading matrix metalloproteinase-1 promoter variants are the plausible candidates, and both are untested here.

  • Sex-based differences: All published human exposure is in women, most of it perimenopausal or postmenopausal. No dosing difference is established for men, and none is mechanistically expected.

  • Age considerations: Testing covered ages 19–65. Beyond 65 the barrier is drier and turnover slower, so a longer trial period is reasonable before judging; no adjusted regimen exists.

  • Baseline biomarkers: Instrument-measured elasticity and water loss through the skin before starting determine whether a change can be detected at all, since the study population was selected for measurable laxity.

  • Pre-existing conditions: Protocols control active inflammatory facial dermatoses first; inflamed skin both tolerates leave-on formulas poorly and invalidates any firmness measurement taken during a flare.

Discontinuation & Cycling

  • Lifelong or short-term: Use is open-ended and cosmetic. Nothing accumulates, and no study has followed the skin after stopping, so any measured gain is presumed to fade as matrix turnover continues.

  • Withdrawal effects: None reported or expected. The peptide has no receptor occupancy to rebound from, and the one controlled trial recorded no events on stopping the lotion.

  • Tapering: Not applicable. A leave-on cosmetic can be stopped outright; tapering schedules exist for agents with adaptive physiological responses, which this is not.

  • Cycling: Not indicated. No tolerance or receptor downregulation has been described, so pausing offers nothing beyond a chance to see whether the effect was real.

  • Reassessment point: A fixed 12-week review is the practical alternative to cycling — long enough to exceed the 56-day manufacturer window, short enough to limit spend on an unverified active.

Sourcing and Quality

  • Identifying it on a label: Finished products list the peptide under its International Nomenclature of Cosmetic Ingredients name, acetyl tetrapeptide-2. Its position near the end of the list signals a fraction of a percent of actual peptide.

  • Raw-material grade: Supplier solutions such as Uplevity and Thymulen-4 are dilute, preservative-free aqueous solutions, not neat peptide. The supplier document that settles it is a certificate of analysis with identity confirmation and purity of at least 95%.

  • Reputable sources: Lipotec, part of Lubrizol, is the originating manufacturer; Lotioncrafter and MakingCosmetics distribute small quantities to formulators. Compounding pharmacies are not relevant, as this is not a prescription preparation.

  • Third-party testing: Cosmetics rarely carry independent verification of active content, and no certification programme covers this peptide, so the ingredient list and supplier documentation are the only checks available.

  • Research-chemical vendors: Sites selling the peptide as an injectable or oral “research” product supply material intended for neither use, without cosmetic-grade purity or endotoxin control.

  • Stability on the shelf: Opaque, airless packaging preserves the active; jars do not. The peptide degrades outside pH 5–8 and above 40 °C, so heat-exposed or acid-shifted products may contain little intact material.

Practical Considerations

  • Time to effect: The manufacturer’s endpoints were measured at 56 days; the hair trial saw separation at weeks 4 to 8. Anything judged before 8 weeks reflects hydration from the vehicle, not matrix change.

  • Common pitfall — expecting injectable-scale change: The reported effects are instrument-measured and modest. Treating a cosmetic peptide as an alternative to a procedure guarantees disappointment.

  • Common pitfall — formula blindness: Many products list the peptide far down the ingredient list at token levels, or pair it with low-pH acids that degrade it, so the tested conditions are never reproduced.

  • Common pitfall — dropping the basics: Sun protection and retinoids carry the documented effect on photoaged skin; replacing rather than supplementing them trades measured benefit for an unmeasured one.

  • Regulatory status: A cosmetic ingredient in both the United States and the European Union, listed for skin conditioning. The Food and Drug Administration does not review cosmetic ingredients before market; European Regulation 1223/2009 requires a safety assessment by the responsible person.

  • Safety review coverage: The Cosmetic Ingredient Review panel, funded by the industry’s own trade association, has assessed related acetylated cosmetic peptides but has published no assessment of acetyl tetrapeptide-2 specifically.

  • Cost and access: Widely available and inexpensive — about $10 for 8 g of supplier solution, $30–$120 for finished serums. Neither this nor cosmetic-indication retinoids are reimbursed, so no institutional payer has an incentive favouring either.

Interaction with Foundational Habits

  • Sleep: Indirect, potentiating. Sleep restriction slows barrier recovery and raises evening water loss through the skin, blunting any measurable gain. No component of the peptide affects sleep, and no timing constraint applies to a topical.

  • Nutrition: Indirect, potentiating. Collagen and elastin synthesis depends on adequate protein, vitamin C and zinc; a deficit caps what any matrix-directed ingredient can do. Oral collagen peptides act on the same endpoints and confound attribution when started together.

  • Exercise: Indirect, none-to-blunting. Sweat and friction remove surface product and shorten contact time; applying after post-exercise cleansing preserves it. No effect on training adaptation is plausible, given negligible systemic exposure.

  • Stress management: Indirect, blunting. Sustained cortisol elevation impairs barrier repair and accelerates collagen breakdown, working directly against the claimed endpoint. The peptide itself has no reported effect on the stress response.

Monitoring Protocol & Defining Success

Because this is a cosmetic applied to the surface, monitoring is instrumental and photographic rather than laboratory-based; no blood test tracks it. Before starting, the useful baseline is a set of standardized photographs in fixed lighting and position, an instrument reading of skin elasticity and hydration at the site to be treated, and a barrier reading, ideally taken on two separate days to capture day-to-day variation. A record of current products and any past reactions completes it. Ongoing, the cadence follows the evidence: reassess at week 4 for tolerance only, then at weeks 8 and 12 for effect, then every 6 months if continued. Success is a change that exceeds the measurement noise on repeat readings and is visible in matched photographs, not a subjective impression gathered in a bathroom mirror.

Biomarker Optimal Functional Range Why Measure It? Context/Notes
Skin elasticity (cutometer R2) No established universal target; the marker is a rise from the individual’s own baseline exceeding the device’s repeat-measure variation The endpoint the firmness claim rests on R2 is the share of skin deformation that springs back; readings are taken at a fixed site at the same time of day; values fall with age and sun exposure
Transepidermal water loss (TEWL) 10–20 g/m²/h on facial skin Detects barrier disruption before visible irritation TEWL is the water evaporating through the skin; measured after 20 minutes acclimatization in a stable room; conventional laboratories report a wider normal range
Stratum corneum hydration (corneometer, arbitrary units) Above 45 arbitrary units on the cheek Separates vehicle hydration from genuine matrix change Values of 30–45 indicate dry skin; fasting is irrelevant, but no product is applied for 12 hours beforehand
Standardized photography and wrinkle grading No numeric target; the reference point is an improvement in matched images at 8 and 12 weeks The outcome that actually matters to the user Lighting, distance, expression and time of day are held fixed; morning images exaggerate puffiness
Skin surface pH 4.5–5.5 An acid mantle outside this range signals barrier stress from the routine Conventional references accept 4.0–6.0; measured before cleansing
Patch test, if a reaction occurs Negative to all components Identifies the responsible allergen rather than blaming the peptide Requires a dermatology clinic, which needs the finished product and its full ingredient list

Qualitative markers worth tracking alongside the instruments:

  • How makeup sits across the cheek and jawline by late afternoon
  • Morning puffiness and how quickly it settles
  • Any stinging, tightness or warmth in the first 10 minutes after application
  • Subjective firmness on waking, recorded the same way each week
  • Whether other people notice a change without being prompted

Emerging Research

  • The one registered trial involving this peptide: NCT04652232 enrolled 100 women with telogen effluvium and compared a scalp lotion containing it against shampoo alone; completed, and published in 2021. No facial-skin equivalent is registered.

  • Registry opacity as a limitation: NCT06143033, a completed 35-participant eye-serum study, lists only “Acetyl Tetrapeptide” among 20-odd ingredients in a single-arm, unblinded design — the kind of entry that cannot settle attribution.

  • The design that could settle it: NCT07614698 is recruiting 30 healthy volunteers for a randomized, placebo-controlled forearm study of a different acetylated peptide, with each participant serving as their own control. The same design applied here would be decisive.

  • Delivery as the rate-limiting step: Work reviewed by Pintea et al., 2025 on microneedles, liposomes and nanoemulsions could strengthen the case by getting water-loving peptides past the barrier that currently limits them.

  • Evidence that could weaken the case: Nukaly et al., 2026 found the pooled wrinkle benefit of peptides driven by oral rather than topical formulations, and Zdrada-Nowak et al., 2025 document how poorly a comparable acetylated peptide penetrates skin.

  • Independent replication of the cell work: The stiffness finding of Kobiela et al., 2018 has not been repeated by another group, and whether it corresponds to anything measurable in living skin is open.

Conclusion

Acetyl tetrapeptide-2 is a laboratory-made fragment of a thymus messenger, sold to cosmetic manufacturers as a firming and renewal ingredient for skin and scalp products. The case for it rests mainly on laboratory work in cultured skin cells and on testing run by the company that sells the raw material. The single study in people that included a comparison group used a scalp lotion in which this peptide was one active among several, so its share of the result cannot be separated out. No independent, published study has measured facial firmness, elasticity or lines with this peptide as the only thing that changed.

Most of what is published about it comes from parties that profit from its use — the ingredient supplier, and the supplement and skincare sellers that feature it — while the panel that reviews cosmetic ingredient safety is funded by the industry itself and has never assessed this one. That does not make the claims wrong; it means nobody without a stake has checked them.

Tolerance in the published human exposure was good, and the molecule is large and water-loving enough that little of it is expected to pass the outer skin layer, which caps both the plausible benefit and the plausible harm. What remains is an inexpensive, low-risk ingredient with an unresolved and largely unmeasured effect.

Top - Benefits - Risks - Protocol